Mostrar el registro sencillo del ítem
dc.contributor.author | Del Rio-Sancho, S. | es_ES |
dc.contributor.author | Serna-Jiménez, C.E. | es_ES |
dc.contributor.author | Sebastián-Morelló, M. | es_ES |
dc.contributor.author | Calatayud-Pascual, M.A. | es_ES |
dc.contributor.author | Balaguer-Fernández, C. | es_ES |
dc.contributor.author | Femenia-Font, A. | es_ES |
dc.contributor.author | Kalia, Y.N. | es_ES |
dc.contributor.author | MERINO SANJUÁN, VIRGINIA | es_ES |
dc.contributor.author | Lopez-Castellano, A. | es_ES |
dc.date.accessioned | 2020-11-05T04:32:59Z | |
dc.date.available | 2020-11-05T04:32:59Z | |
dc.date.issued | 2017-01-30 | es_ES |
dc.identifier.issn | 0378-5173 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10251/154101 | |
dc.description.abstract | [EN] Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist used in the treatment of moderate to severe dementia including the symptoms of Alzheimer's disease (AD). It is administered orally but compliance, swallowing problems and the routine use of multiple medications in elderly AD patients means that an alternative route of administration would be of interest. The aim of the present. study was to develop memantine hydrochloride occlusive transdermal therapeutic systems (TI'S) for passive and iontophoretic delivery across the skin. Polyvinyl pyrrolidone (PVP) and a mixture with polyvinyl alcohol (PVA) were employed as polymeric matrices. The study involved the TTS characterization in addition to quantification of the memantine transport across porcine skin in vitro. The evaluation of the ITS physical properties suggested that systems were made more mechanically resistant by including PVA (6%) or high concentrations of PVP (24%). Moreover, a linear correlation was observed between the concentration of PVP and the bioadhesion of the systems. Drug delivery expefiments showed that the highest transdermal flux provided by a passive TTS (PVP 24% w/w limonene) was 8.89 +/- 0.81 mu g cm(-2) h(-1) whereas the highest iontophoretic transport was 46.4 +/- 3.6 mu g cm(-2) h(-1). These innovative TTS would enable two dosage regimens that could lead to therapeutic plasma concentrations. | es_ES |
dc.description.sponsorship | The authors wish to thank the "Generalitat Valenciana" (AP-114/09; AP-155/10; AP-175/11) and the "Universidad CEU Cardenal Herrera" for their financial support. The authors also thank Pharsight corp. for the academic license of WinNonlin 5.0.1. | es_ES |
dc.language | Inglés | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation.ispartof | International Journal of Pharmaceutics | es_ES |
dc.rights | Reserva de todos los derechos | es_ES |
dc.subject | Memantine | es_ES |
dc.subject | Transdermal delivery | es_ES |
dc.subject | Occlusive-systems | es_ES |
dc.subject | Chemical penetration enhancers | es_ES |
dc.subject | Iontophoresis | es_ES |
dc.title | Transdermal therapeutic systems for memantine delivery. Comparison of passive and iontophoretic transport | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | 10.1016/j.ijpharm.2016.11.038 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/Generalitat Valenciana//AP-114%2F09/ES/Estudio de la administración transdérmica de memantina para el tratamiento de la enfermedad de Alzheimer/ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/Generalitat Valenciana//AP-155%2F10/ES/Estudio de la administración transdérmica de memantina para el tratamiento de la enfermedad de Alzheimer./ | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/Generalitat Valenciana//AP-175%2F11/ES/Desarrollo de un parche transdérmico de memantina para el tratamiento de la enfermedad de Alzheimer en fases avanzadas/ | es_ES |
dc.rights.accessRights | Cerrado | es_ES |
dc.description.bibliographicCitation | Del Rio-Sancho, S.; Serna-Jiménez, C.; Sebastián-Morelló, M.; Calatayud-Pascual, M.; Balaguer-Fernández, C.; Femenia-Font, A.; Kalia, Y.... (2017). Transdermal therapeutic systems for memantine delivery. Comparison of passive and iontophoretic transport. International Journal of Pharmaceutics. 517(1-2):104-111. https://doi.org/10.1016/j.ijpharm.2016.11.038 | es_ES |
dc.description.accrualMethod | S | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.ijpharm.2016.11.038 | es_ES |
dc.description.upvformatpinicio | 104 | es_ES |
dc.description.upvformatpfin | 111 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | es_ES |
dc.description.volume | 517 | es_ES |
dc.description.issue | 1-2 | es_ES |
dc.identifier.pmid | 27865983 | es_ES |
dc.relation.pasarela | S\365980 | es_ES |
dc.contributor.funder | Generalitat Valenciana | es_ES |
dc.contributor.funder | Universidad CEU Cardenal Herrera | es_ES |